Description
Deracoxib is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, anticoagulant, and anticancer chemotherapeutic activities. Deracoxib inhibits COX-2 and is clinically used to treat osteoarthritis in veterinary subjects. Deracoxib also decreases platelet aggregation in vivo. In mammary tumor cells, deracoxib induces apoptosis, decreases cell viability, and induces G0/G1 phase cell cycle arrest; similarly, this compound inhibits tumor growth in animal models of bladder transitional cell carcinoma.
References
Ustün Alkan F, Ustüner O, et al. The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal. 2012;2012:976740. PMID: 23251109.
Bienhoff SE, Smith ES, Roycroft LM, et al. Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg. 2012 Apr;41(3):336-44. PMID: 22225463.
McMillan SK, Boria P, Moore GE, et al. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc. 2011 Oct 15;239(8):1084-9. PMID: 21985349.
Blois SL, Allen DG, Wood RD, et al. Effects of aspirin, carprofen, deracoxib, and meloxicam on platelet function and systemic prostaglandin concentrations in healthy dogs. Am J Vet Res. 2010 Mar;71(3):349-58. PMID: 20187838.
